Cessation and relapse prevention trial: vaporised nicotine products for people on opiate substitution therapy, or who are living with Hepatitis C or HIV

Coral Gartner; Mark A. Boyd; Billie Bonevski; Charles Gilks; Ron Borland; Ryan J. Courtney; Linda Cobiac; Hayden McRobbie; Peter Baker; Jochen Mueller

doi:10.1111/dar.12862

Cessation and relapse prevention trial: vaporised nicotine products for people on opiate substitution therapy, or who are living with Hepatitis C or HIV

Coral Gartner, Mark A. Boyd, Billie Bonevski, Charles Gilks, Ron Borland, Ryan J. Courtney, Linda Cobiac, Hayden McRobbie, Peter Baker, Jochen Mueller

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Compared to the general population, smoking prevalence is higher among people who are on opiate substitution therapy or living with HCV or HIV. This trial will compare the effectiveness, safety and cost- effectiveness of providing VNPs as a nicotine replacement therapy to these populations. Two conditions will be compared:
(i) concurrent delivery of VNP with standard smoking cessation treatment; versus, (ii) sequential delivery of VNP 6 months after quit attempt with standard smoking cessation treatment for participants who do not achieve or maintain abstinence after baseline quit attempt.

Original language	English
Pages (from-to)	S6
Number of pages	1
Journal	Drug and Alcohol Review
Volume	37
Issue number	S3
DOIs	https://doi.org/10.1111/dar.12862
Publication status	Published - Nov 2018
Externally published	Yes
Event	2018 Australasian Professional Society on Alcohol and other Drugs Conference - Auckland, New Zealand Duration: 4 Nov 2018 → 7 Nov 2018

Keywords

Opiate substitution treatment
cessation support
relapse prevention
smoking prevalence
Hepatitis C
HIV
Nicotine Replacement Therapy (NRT)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/dar.12862Licence: In Copyright

Cite this

@article{9e38511cba524ef690bb41870d69dd0e,

title = "Cessation and relapse prevention trial: vaporised nicotine products for people on opiate substitution therapy, or who are living with Hepatitis C or HIV",

abstract = "Compared to the general population, smoking prevalence is higher among people who are on opiate substitution therapy or living with HCV or HIV. This trial will compare the effectiveness, safety and cost- effectiveness of providing VNPs as a nicotine replacement therapy to these populations. Two conditions will be compared:(i) concurrent delivery of VNP with standard smoking cessation treatment; versus, (ii) sequential delivery of VNP 6 months after quit attempt with standard smoking cessation treatment for participants who do not achieve or maintain abstinence after baseline quit attempt.",

keywords = "Opiate substitution treatment, cessation support, relapse prevention, smoking prevalence, Hepatitis C, HIV, Nicotine Replacement Therapy (NRT)",

author = "Coral Gartner and Boyd, {Mark A.} and Billie Bonevski and Charles Gilks and Ron Borland and Courtney, {Ryan J.} and Linda Cobiac and Hayden McRobbie and Peter Baker and Jochen Mueller",

year = "2018",

month = nov,

doi = "10.1111/dar.12862",

language = "English",

volume = "37",

pages = "S6",

journal = "Drug and Alcohol Review",

issn = "0959-5236",

publisher = "Carfax Publishing Co",

number = "S3",

note = "2018 Australasian Professional Society on Alcohol and other Drugs Conference, APSAD 2018 ; Conference date: 04-11-2018 Through 07-11-2018",

}

TY - JOUR

T1 - Cessation and relapse prevention trial: vaporised nicotine products for people on opiate substitution therapy, or who are living with Hepatitis C or HIV

AU - Gartner, Coral

AU - Boyd, Mark A.

AU - Bonevski, Billie

AU - Gilks, Charles

AU - Borland, Ron

AU - Courtney, Ryan J.

AU - Cobiac, Linda

AU - McRobbie, Hayden

AU - Baker, Peter

AU - Mueller, Jochen

PY - 2018/11

Y1 - 2018/11

N2 - Compared to the general population, smoking prevalence is higher among people who are on opiate substitution therapy or living with HCV or HIV. This trial will compare the effectiveness, safety and cost- effectiveness of providing VNPs as a nicotine replacement therapy to these populations. Two conditions will be compared:(i) concurrent delivery of VNP with standard smoking cessation treatment; versus, (ii) sequential delivery of VNP 6 months after quit attempt with standard smoking cessation treatment for participants who do not achieve or maintain abstinence after baseline quit attempt.

AB - Compared to the general population, smoking prevalence is higher among people who are on opiate substitution therapy or living with HCV or HIV. This trial will compare the effectiveness, safety and cost- effectiveness of providing VNPs as a nicotine replacement therapy to these populations. Two conditions will be compared:(i) concurrent delivery of VNP with standard smoking cessation treatment; versus, (ii) sequential delivery of VNP 6 months after quit attempt with standard smoking cessation treatment for participants who do not achieve or maintain abstinence after baseline quit attempt.

KW - Opiate substitution treatment

KW - cessation support

KW - relapse prevention

KW - smoking prevalence

KW - Hepatitis C

KW - HIV

KW - Nicotine Replacement Therapy (NRT)

UR - https://apsadconference2021.com.au/abstract-submissions/

U2 - 10.1111/dar.12862

DO - 10.1111/dar.12862

M3 - Meeting Abstract

SN - 0959-5236

VL - 37

SP - S6

JO - Drug and Alcohol Review

JF - Drug and Alcohol Review

IS - S3

T2 - 2018 Australasian Professional Society on Alcohol and other Drugs Conference

Y2 - 4 November 2018 through 7 November 2018

ER -

Cessation and relapse prevention trial: vaporised nicotine products for people on opiate substitution therapy, or who are living with Hepatitis C or HIV

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this